E. Ferreira and A. Blanc, Grossesse et allaitement : guide thérapeutique. CHU sainte Justine, Québec : Broché. 2007. adverse birth outcomes following gestional exposure to statins, Am J Med Genet, vol.131, pp.287-298, 2004.

P. Pollack, K. Shields, D. Burnett, M. Osborne, M. Cunningham et al., Pregnancy outcomes after maternal exposure to simvastatin and lovastatin, Birth Defects Research Part A: Clinical and Molecular Teratology, vol.33, issue.11, pp.888-96, 2005.
DOI : 10.1002/bdra.20181

. Vidal-recos, Troisième édition, pp.498-509, 2009.

. Institut-de-veille-sanitaire, Etude nationale nutrition et santé, 2006.

S. Lestavel and A. Tailleux, Structure et métabolisme des lipoprotéines. Biochimie hématologie. 3ème édition. Collection le moniteur internat, pp.173-96

C. Huissoud, J. Robert, and N. Bakrin, Hypertriglyc??rid??mies gestationnelles s??v??res??: complications et principes de prise en charge, Journal de Gyn??cologie Obst??trique et Biologie de la Reproduction, vol.37, issue.5, pp.517-537, 2008.
DOI : 10.1016/j.jgyn.2007.12.007

G. Turpin, Troubles du métabolisme des lipides. Pathologies maternelles et grossesse. MEDSI/MC grow hill, pp.180-86

I. Durack-bown and . L-'hyperlipidémie-gestationnelle, Sang Thrombose Vaisseaux, pp.635-676, 1996.

S. Teelucksingh, E. Youssef, J. Sohan, K. Ramsewak, and S. , Prolonged inadvertent pravastatine use in pregnancy, J reprotox, vol.11, p.3, 2003.

J. Rutinshauser, Les effets pléiotropes des statines, Forum Med Suisse, vol.8, issue.10, pp.187-90, 2008.

E. Petersen, A. Mitchell, J. Carey, M. Werker, C. Louik et al., Maternal exposure to statins and risk for birth defects: A case-series approach, American Journal of Medical Genetics Part A, vol.116, issue.20, pp.2701-2706, 2008.
DOI : 10.1002/ajmg.a.32493

B. Ofori, E. Rey, and A. Bérard, Risk of congenital anomalies in pregnant users of statin drugs, British Journal of Clinical Pharmacology, vol.142, issue.4, pp.496-509, 2007.
DOI : 10.1067/mob.2003.223

P. Wolfgang, S. Schloemp, K. Sterzik, and F. Stoz, Pregnancies outcome after medication with HMG CoA Reductase inhibitors in the First trimester. Reprod Toxicology (abs), pp.254-55, 2004.

U. Winterfeld, Pregnancy outcome following maternal exposure to statins: a multicentre prospective study, BJOG: An International Journal of Obstetrics & Gynaecology, vol.21, issue.Suppl 4, 2010.
DOI : 10.1111/1471-0528.12066

N. Taguchi, E. Rubin, and A. Hosokawa, Prenatal exposure to HMG-CoA reductase inhibitors: Effects on fetal and neonatal outcomes, Reproductive Toxicology, vol.26, issue.2, pp.175-182, 2008.
DOI : 10.1016/j.reprotox.2008.06.009

G. Briggs, R. Freeman, and S. Yaffe, Atorvastatine Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, pp.106-113, 2008.

G. Briggs, R. Freeman, and Y. S. Pravastatine, Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, pp.1146-1153, 2008.

G. Briggs, R. Freeman, and Y. S. Fluvastatine, Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, pp.578-587, 2008.

G. Briggs, R. Freeman, and S. Yaffe, Simvastatine Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, pp.1258-60, 2008.

G. Briggs, R. Freeman, and S. Yaffe, Introduction. Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, 2008.

J. Henck, W. Craft, A. Black, J. Colgin, and J. Anderson, Pre- and Postnatal Toxicity of the HMG-CoA Reductase Inhibitor Atorvastatin in Rats, Toxicological Sciences, vol.41, issue.1, pp.88-99, 1998.
DOI : 10.1093/toxsci/41.1.88

A. 44-kazmin, F. Garcia-bournissen, and G. Koren, Risks of statin use during pregnancy : a systématic review, JOGC, pp.906-914, 2007.

A. Hosokawa, Use of lipid-lowering agents (statins) during pregnancy, 2010.

P. Mc-elhatton, Preliminary data on exposure to statins during pregnancy, Reprod Toxicol, vol.20, issue.3, pp.471-472, 2005.

R. Hrab, H. Hartman, R. Cox, and . Jr, Prevention of fluvastatin-induced toxicity, mortality, and cardiac myopathy in pregnant rats by mevalonic acid supplementation, Teratology, vol.11, issue.1, pp.19-26, 1994.
DOI : 10.1002/tera.1420500104

J. Seguin and P. Samuels, Fluvastatin exposure during pregnancy, Obstet Gynecol, vol.93, p.847, 1999.
DOI : 10.1097/00006250-199905001-00026

A. Ghidini, S. Sicherer, and J. Willner, Congenital abnormalities (VATER) in baby born to mother using lovastatin, The Lancet, vol.339, issue.8806, p.1416, 1992.
DOI : 10.1016/0140-6736(92)91237-3

J. N. Manson, C. Freyssinges, M. Ducrocq, and W. Stephenson, Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy, Reproductive Toxicology, vol.10, issue.6, pp.439-485, 1996.
DOI : 10.1016/S0890-6238(96)00130-X

S. Teelucksingh, J. El-youssef, K. Sohan, and S. Ramsewak, Prolonged inadvertent pravastatin use in pregnancy, Reproductive Toxicology, vol.18, issue.2, pp.299-300, 2004.
DOI : 10.1016/j.reprotox.2003.11.003

C. Freyssinges and M. Ducrocq, Simvastatine et grossesse, Therapie, vol.51, pp.537-579, 1996.

J. 61-naitoh, T. Misawa, N. Shibata, T. Nishigaki, S. Ozawa et al., Reproduction studies of bezafibrate (2nd report) -teratological study in rats, Kiso to Rinsho, vol.22, p.4415, 1988.

H. Tuchmann-duplessis, H. Hiss, and J. Legros, Teratological and prenatal toxicity evaluations of a new hypolipemic agent. (abs), Teratology, vol.14, p.376, 1976.

H. Kobayashi, S. Kamada, K. Shimpo, S. Imoto, Y. Noguchi et al., Teratological study of orally administered fenofibrate in rats, Chiryo, 1995.

G. Briggs, R. Freeman, and Y. S. Gemfibrozil, Drugs in Pregnancy and Lactation: A reference Guide to Fetal and Neonatal Risk, pp.613-617, 2008.

A. Shali, K. Wang, J. Faser, F. Huff, M. Wolfe et al., Successful pregnancy outcome in a patient with severe chylomicronemia due to compound heterozygosity for mutant lipoprotein lipase, Clinical Biochemistry, vol.35, issue.2, pp.125-155, 2002.
DOI : 10.1016/S0009-9120(02)00283-7

F. Rosa, Anti-cholesterol agent pregnancy exposure outcomes, Reproductive Toxicology, vol.8, issue.5, pp.445-451, 1994.
DOI : 10.1016/0890-6238(94)90091-4

P. Jaber, B. Wilson, D. Johns, P. Cooper, and J. Ferguson, Eruptive xanthomas during pregnancy, Journal of the American Academy of Dermatology, vol.27, issue.2, pp.300-302, 1992.
DOI : 10.1016/0190-9622(92)70185-I

A. Morse and M. Whitaker, Successful pregnancy in a woman with lipoatrophic diabetes mellitus. A case report, J Reprod Med, vol.45, pp.850-852, 2000.

T. Barozzino, E. Kotzer, M. Sgro, G. Koren, and D. Chitayat, Situs Inversus, Encephalocele and Jejunal Atresia Following Exposure to Gemfibrozil in Pregnancy, Paediatrics & Child Health, vol.7, issue.suppl_A, p.54, 2002.
DOI : 10.1093/pch/7.suppl_A.55Ac

S. Koda, K. Anabuki, T. Miki, S. Kahi, and N. Takahashi, Reproductive studies on cholestyramine, Kiso to Rinsho, vol.16, 1982.

L. Sadler, M. Lane, and R. North, Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy, BJOG: An International Journal of Obstetrics and Gynaecology, vol.99, issue.2, pp.169-70, 1995.
DOI : 10.1111/j.1471-0528.1995.tb09077.x

F. Rosa, Anti-cholesterol agent pregnancy exposure outcomes, Reproductive Toxicology, vol.8, issue.5, pp.445-446, 1994.
DOI : 10.1016/0890-6238(94)90091-4

. Teris, Oméga 3. www.micromedex.com, 2010.

. Reprotox, Oméga 3. www.micromedex.com, 2010.

W. Larsen, Embryologie humaine, deuxième édition édition, Boeck, 2003.